ORION Biotechnology Switzerland Sàrl

Orion Biotechnology is discovering and developing G Protein-Coupled Receptor (GPCR) targeted therapeutics for the treatment of cancer and other serious diseases.
Orions novel drug modality involves precision engineering ligands of peptide and protein GPCRs, providing an enhanced solution to targeting previously-undrugged GPCRs. This approach is supported by one of the fastest drug discovery platforms in industry and represents a large opportunity to discover and develop a new generation of GPCR-targeted medicines.